Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Lenvatinib in Chinese HCC Patients
NCT02953743Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Observed Concentration at Day 15, Time to Maximum Concentration at Day 15 and 6 more. Started Sep 2016; status: completed.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02953743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02953743.